Vitiligo Pipeline Update: Teva Set To Advance Its Anti-IL-15 Antibody Into Phase 2b Development
Teva Pharmaceutical Industries Ltd. is advancing TEV-’408, an investigational anti-interleukin (IL)-15 monoclonal antibody, into Phase 2b development in…